Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PBF 1129

Next Previous
X
Search
Drug Profile

PBF 1129

Alternative Names: PBF-1129

Latest Information Update: 28 Feb 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Palobiofarma
  • Developer Ohio State University; Palobiofarma
  • Class Antifibrotics; Antineoplastics
  • Mechanism of Action Adenosine A2B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • No development reported Idiopathic pulmonary fibrosis

Most Recent Events

  • 28 Feb 2025 No recent reports of development identified for phase-I development in Idiopathic-pulmonary-fibrosis in Spain (PO)
  • 17 Jul 2023 Phase-II clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease) in USA (PO) prior to July 2023 (Palobiofarma pipeline, July 2023)
  • 10 Feb 2022 National Cancer Institute plans a phase I trial for Non-small cell lung cancer (Metastatic disease, Late-stage disease, Recurrent) in USA (PO) by April 2022 (NCT05234307)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top